BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ascentage Pharma Group Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Ascentage Pharma Group Inc.'s dru
 gs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05147467-2883@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lisaftoclax: Phase 2 readout est. (NCT05147467)
DESCRIPTION:Lisaftoclax\, phase 2\, Relapsed/Refractory Chronic Lymphocytic
  Leukemia.\nStudy: Study of APG-2575 in Patients With Relapsed/Refractory 
 CLL/SLL\nEstimated primary completion: December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05147467
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06104566-2883@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lisaftoclax: Phase 3 readout est. (NCT06104566)
DESCRIPTION:Lisaftoclax\, phase 3.\nStudy: Global Trial in APG2575 for Pati
 ents With CLL/SLL\nEstimated primary completion: 31 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06104566
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06640361-2925@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Olverembatinib: Phase 3 readout est. (NCT06640361)
DESCRIPTION:Olverembatinib\, phase 3.\nStudy: A Study of Olverembatinib in 
 SDH-deficient GIST.\nEstimated primary completion: 31 March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/olverembatinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06640361
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05701306-2883@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Lisaftoclax: Phase 1/2 readout est. (NCT05701306)
DESCRIPTION:Lisaftoclax\, phase 1/2.\nStudy: APG-115 Alone or in Combinatio
 n With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors\n
 Estimated primary completion: 1 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05701306
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06423911-2925@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Olverembatinib: Phase 3 readout est. (NCT06423911)
DESCRIPTION:Olverembatinib\, phase 3\, Chronic Myeloid Leukemia.\nStudy: St
 udy of Olverembatinib (HQP1351) in Patients With CML-CP\nEstimated primary
  completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/olverembatinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06423911
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06319456-2883@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lisaftoclax: Phase 3 readout est. (NCT06319456)
DESCRIPTION:Lisaftoclax\, phase 3.\nStudy: A Study of Lisaftoclax (APG-2575
 ) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnose
 d CLL/SLL.\nEstimated primary completion: August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/lisaftoclax#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06319456
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06051409-2925@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Olverembatinib: Phase 3 readout est. (NCT06051409)
DESCRIPTION:Olverembatinib\, phase 3.\nStudy: A Study of Olverembatinib in 
 Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)\nEstimated primary compl
 etion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/olverembatinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06051409
URL:https://assetmemo.bio/drug/olverembatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06389292-2883@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20280525
DTEND;VALUE=DATE:20280526
SUMMARY:Lisaftoclax: Phase 3 readout est. (NCT06389292)
DESCRIPTION:Lisaftoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Pivot
 al Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatm
 ent of Acute Myeloid Leukemia\nEstimated primary completion: 25 May 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lisaftoclax#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06389292
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04501120-2883@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Lisaftoclax: Phase 1/2 readout est. (NCT04501120)
DESCRIPTION:Lisaftoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Pa
 tients Relapsed/Refractory AML\nEstimated primary completion: September 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lisaftoclax#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04501120
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06641414-2883@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Lisaftoclax: Phase 3 readout est. (NCT06641414)
DESCRIPTION:Lisaftoclax\, phase 3.\nStudy: Lisaftoclax (APG-2575) Combined 
 With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelo
 dysplastic Syndrome (GLORA-4).\nEstimated primary completion: June 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/lisaftoclax#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06641414
URL:https://assetmemo.bio/drug/lisaftoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
